-+ 0.00%
-+ 0.00%
-+ 0.00%

Evotec, Bristol Myers Squibb Secure Second FDA IND Clearance in Protein Degradation Partnership

PUBT·11/19/2026 06:31:23
Listen to the news
Evotec, Bristol Myers Squibb Secure Second FDA IND Clearance in Protein Degradation Partnership
  • Evotec and Bristol Myers Squibb secured FDA clearance for a second investigational drug under their protein-degradation partnership.
  • The molecular glue drug candidate is expected to enter a Phase 1 trial in 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evotec SE published the original content used to generate this news brief via EQS News (Ref. ID: corporate_2438000_de) on November 19, 2026, and is solely responsible for the information contained therein.